Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $72.27 in the prior trading day, Corcept Therapeutics Inc (NASDAQ: CORT) closed at $67.54, down -6.54%. In other words, the price has decreased by -$6.54 from its previous closing price. On the day, 1.9 million shares were traded. CORT stock price reached its highest trading level at $71.55 during the session, while it also had its lowest trading level at $66.5.
Ratios:
Our goal is to gain a better understanding of CORT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 40.43. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 3.07. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 01 ’25 when Guyer William sold 100 shares for $73.50 per share. The transaction valued at 7,350 led to the insider holds 5,487 shares of the business.
Lyon Joseph Douglas sold 100 shares of CORT for $7,350 on Jul 01 ’25. The insider now owns 10,066 shares after completing the transaction at $73.50 per share. On Jul 01 ’25, another insider, Maduck Sean, who serves as the insider of the company, sold 205 shares for $73.45 each. As a result, the insider received 15,058 and left with 17,705 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 7162809344 and an Enterprise Value of 7467752448. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 58.63, and their Forward P/E ratio for the next fiscal year is 25.39. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.45 while its Price-to-Book (P/B) ratio in mrq is 10.48. Its current Enterprise Value per Revenue stands at 10.895 whereas that against EBITDA is 67.079.
Stock Price History:
The Beta on a monthly basis for CORT is 0.21, which has changed by 1.2591972 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $29.42. The 50-Day Moving Average of the stock is -6.98%, while the 200-Day Moving Average is calculated to be 10.65%.
Shares Statistics:
The stock has traded on average 1.53M shares per day over the past 3-months and 2147390 shares per day over the last 10 days, according to various share statistics. A total of 105.98M shares are outstanding, with a floating share count of 93.80M. Insiders hold about 11.55% of the company’s shares, while institutions hold 78.70% stake in the company. Shares short for CORT as of 1749772800 were 12652014 with a Short Ratio of 8.27, compared to 1747267200 on 12481476. Therefore, it implies a Short% of Shares Outstanding of 12652014 and a Short% of Float of 16.08.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is $0.41, with high estimates of $0.46 and low estimates of $0.32.
Analysts are recommending an EPS of between $1.52 and $1.27 for the fiscal current year, implying an average EPS of $1.38. EPS for the following year is $2.66, with 4.0 analysts recommending between $3.96 and $1.12.
Revenue Estimates
4 analysts predict $199.39M in revenue for the current quarter. It ranges from a high estimate of $210M to a low estimate of $184.58M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $163.8MFor the next quarter, 4 analysts are estimating revenue of $247.54M. There is a high estimate of $261M for the next quarter, whereas the lowest estimate is $239.15M.
A total of 4 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $901.3M, while the lowest revenue estimate was $894.2M, resulting in an average revenue estimate of $899.05M. In the same quarter a year ago, actual revenue was $675.04MBased on 4 analysts’ estimates, the company’s revenue will be $1.22B in the next fiscal year. The high estimate is $1.38B and the low estimate is $1.03B.
